Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 50090-5890

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 50090-5890). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figr1 (Figr1)

This text provides information about the interaction of certain drugs, including ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium, with analyte venlafaxine. The PK Fold Change and 90% CI Recommendation are also listed for various parameters. The recommendation for each parameter is either to avoid concomitant use, use with caution, or no dose adjustment needed. The text provides some information about the clinical significance of the interactions but notes that it is unknown in some cases.*

FDA Label Image

Figr2 (Figr2)

This appears to be a table showing different drugs and their effects when taken concomitantly with other drugs. The table includes information on PKFold Change and 90% CI Recommendation for the interacting drugs, as well as information on Cmax and AUC. It also gives recommendations for each interaction, such as whether to avoid concomitant use, monitor blood pressure, or use with caution. However, without additional context or information, it's difficult to derive any further meaning from this text.*

FDA Label Image

Figr3 (Figr3)

This document provides recommendations on dose adjustments for venlafaxine in patients with liver or renal impairments, CYP2D6 polymorphism, and advanced age. For patients with cirrhosis, a reduction of 50% or more of the dose is recommended. For mild to moderate impairments, a 25% to 50% reduction in dose is necessary. For patients undergoing hemodialysis, the dose should be reduced by 50% or more. No dose adjustment is required for patients with CYP2D6 polymorphism, age over 60, or different genders. The document also includes a table showing changes of the analyte PK and fold change relative to the reference value.*

FDA Label Image

Label Image (Lbl500905890)

Product No. 6327-0 is a 30 count bottle of Venlafaxine Hydrochloride extended-release capsules, at a strength of 156 mg. The recommended storage temperature appears to be 68 to 77 degrees Fahrenheit.*

FDA Label Image

Logo1 (Logo1)

FDA Label Image

Logo2 (Logo2)

FDA Label Image

Venlafaxinestructure (Venlafaxinestructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.